Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-COVER II: Dabigatran vs Warfarin for Acute VTE
NCT00680186Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of dabigatran in venous thromboembolism (VTE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE at 6 months. Started Apr 2008; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00680186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00680186.